Abstract
Retinoblastoma (RB), an intraocular tumor of childhood, contains small subpopulation(s) of stem-like cells expressing the ABCG2 drug transporter that can efflux standard chemotherapies. Since chemo-resistant stem-like cells appear to be a driving force in tumor progression and metastasis for a variety of cancers, innovative treatment strategies are necessary to eradicate these rare cell populations. Terminal differentiation, as a means to deplete the pool of stem-like cells in RB, is an intriguing approach to cancer therapeutics. However, the full extent of RB differentiation remains unknown. Differentiation of RB cells has been examined in response to a variety of different agents, including retinoic acid/sodium butyrate, Pigment Epithelial-Derived Factor, as well as Succinylated Concanavalin A. RB cells exhibit morphologic and phenotypic responses to these differentiating agents, although the permanence of these effects is questionable due to reversibility. Further study of differentiation programs may lead to new approaches in the design of strategies to combat the initiation and progression of RB in vivo.
Keywords: Retinoblastoma, cancer stem cell, differentiation, neurons, glia, ntraocular tumor, ABCG2 drug transporter, chemotherapies, chemo-resistant stem-like, retinoic acid/, sodium butyrate, Succinylated Concanavalin, retina, osteosarcoma, chemo-resistant, metastatic stem-like cells, acute myeloid leukemia, breast cancers, brain tumors, human embryonic stem cell markers, neuroectodermal, rhodopsin, arrestin
Current Pharmaceutical Biotechnology
Title: Differentiation Potential of Human Retinoblastoma Cells
Volume: 12 Issue: 2
Author(s): Gail M. Seigel
Affiliation:
Keywords: Retinoblastoma, cancer stem cell, differentiation, neurons, glia, ntraocular tumor, ABCG2 drug transporter, chemotherapies, chemo-resistant stem-like, retinoic acid/, sodium butyrate, Succinylated Concanavalin, retina, osteosarcoma, chemo-resistant, metastatic stem-like cells, acute myeloid leukemia, breast cancers, brain tumors, human embryonic stem cell markers, neuroectodermal, rhodopsin, arrestin
Abstract: Retinoblastoma (RB), an intraocular tumor of childhood, contains small subpopulation(s) of stem-like cells expressing the ABCG2 drug transporter that can efflux standard chemotherapies. Since chemo-resistant stem-like cells appear to be a driving force in tumor progression and metastasis for a variety of cancers, innovative treatment strategies are necessary to eradicate these rare cell populations. Terminal differentiation, as a means to deplete the pool of stem-like cells in RB, is an intriguing approach to cancer therapeutics. However, the full extent of RB differentiation remains unknown. Differentiation of RB cells has been examined in response to a variety of different agents, including retinoic acid/sodium butyrate, Pigment Epithelial-Derived Factor, as well as Succinylated Concanavalin A. RB cells exhibit morphologic and phenotypic responses to these differentiating agents, although the permanence of these effects is questionable due to reversibility. Further study of differentiation programs may lead to new approaches in the design of strategies to combat the initiation and progression of RB in vivo.
Export Options
About this article
Cite this article as:
M. Seigel Gail, Differentiation Potential of Human Retinoblastoma Cells, Current Pharmaceutical Biotechnology 2011; 12 (2) . https://dx.doi.org/10.2174/138920111794295846
DOI https://dx.doi.org/10.2174/138920111794295846 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
Anti-Cancer Agents in Medicinal Chemistry Profiling the Shear Stress of Atherosclerosis; A Genomic View
Current Genomics Stem Cell Fate Decisions: The Role of Heparan Sulfate in the Control of Autocrine and Paracrine Signals
Current Stem Cell Research & Therapy Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Microarray Profiling Analysis Uncovers Common Molecular Mechanisms of Rubella Virus, Human Cytomegalovirus, and Herpes Simplex Virus Type 2 Infections in ECV304 Cells
Current Molecular Medicine Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets Synthesis and In Vitro Antiproliferative Activity of Thiazole-Based Nitrogen Mustards: The Hydrogen Bonding Interaction between Model Systems and Nucleobases
Anti-Cancer Agents in Medicinal Chemistry Receptor Tyrosine Kinases as Target for Anti-Cancer Therapy
Current Pharmaceutical Design Multi-Kinase Inhibitors
Current Medicinal Chemistry Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma
Current Drug Targets Seocalcitol (EB 1089) A Vitamin D Analogue of Anti-cancer Potential. Background, Design, Synthesis, Pre-clinical and Clinical Evaluation
Current Pharmaceutical Design AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives
Current Drug Targets From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs
Current Medicinal Chemistry Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry Viral Carcinogenesis of Oral Region and Recent Trends in Treatment
Recent Patents on Biomarkers